Italia markets closed

AUTL May 2024 7.500 call

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
0,05000,0000 (0,00%)
In data: 09:32AM EDT. Mercato aperto.
Schermo intero
Chiusura precedente0,0500
Aperto0,0500
Denaro0,0000
Lettera0,0500
Prezzo d'esercizio7,50
Scadenza2024-05-17
Min-Max giorno0,0500 - 0,0500
Contratto - Min-MaxN/D
Volume24
Open Interest59
  • GlobeNewswire

    Correction - Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023

    LONDON, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter 2023 financial results and operational highlights before open of US markets on Thursday, November 2, 2023. Management will host a conference call and webcast at 9:00 am ET/1:00 pm GMT to discuss the company’s financial results and provide a general business updat

  • GlobeNewswire

    Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023

    LONDON, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter 2023 financial results and operational highlights before open of US markets on Thursday, November 2, 2023. Management will host a conference call and webcast at 9:00 am ET/1:00 pm GMT to discuss the company’s financial results and provide a general business updat

  • GlobeNewswire

    Autolus Therapeutics announces data from AUTO1/22 trial in pediatric Acute Lymphoblastic Leukemia published in the journal Blood

    Data support utility of AUTO1/22 approach in preventing antigen evasion in pediatric B-ALLComplete responses observed in patients with CD19 negative disease No antigen negative relapse seen in responding patients LONDON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces a publication on the AUTO1/22 Phase 1 study (CARPALL) in Pediatric B-cell Acute Lymphobl